DOCSLIB.ORG

The Effect of Platelet Lysate on Expansion and Differentiation Megakaryocyte Progenitor Cells from Cord Blood CD34+ Enriched Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Original Article Iran J Ped Hematol Oncol. 2021, Vol 11, No 3, 172-182 The Effect of Platelet Lysate on Expansion and Differentiation Megakaryocyte Progenitor Cells from Cord Blood CD34+ enriched Cells Yoda Yaghoubi MSc1,2, Ali Hassanzadeh PhD3, Adel Naimi MSc4, Sepehr Abdolahi MSc5, Mehdi Yousefi PhD2, Leili Aghebati-Maleki PhD6, Majid Zamani MSc7,* 1. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran 2. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 3. Department of Tissue Engineering and Applied Cell Sciences, Tehran University of Medical Sciences, Tehran, Iran 4. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran 5. Department of Biology, Faculty of Science, Azarbaijan Shahid Madani University, Tabriz, Iran 6. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 7. Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Gonabad University of Medical Sciences, Gonabad, Iran *Corresponding author: Mr. Majid Zamani, MSc. of laboratory hematology and blood banking, Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. Email: [email protected]. ORCID ID: 0000-0002-7260-2348 Received: 14 December 2020 Accepted: 09 June 2021 Abstract Background: Umbilical cord blood hematopoietic stem cells (UCB-HSCs) are an attractive source for transplantation. The generation of megakaryocyte-committed cells could lead to shorten period of thrombocytopenia after HSCs transplantation. Platelet lysate (PL) unlike fetal bovine serum (FBS) can prevent immune problems as well as avert transmission of certain diseases to the recipient. In this study, the authors aimed to assess the effect of PL on UCB CD34+ cells expansion and megakaryocyte differentiation. Materials and Methods: In this experimental study, PL prepared and the subsequent isolation of UCB CD34+ cells were done by magnetic cell sorting. The isolated cells were cultivated in Iscove’s Modified Dulbecco’s medium (IMDM) supplemented with PL or FBS. Cell expansion was evaluated using Trypan blue. Furthermore, Flow cytometry using monoclonal antibodies (CD41-FITC and CD42b-PE) and the expression of specific genes including GATA1, GATA2, FLI1, NFE2, and RUNX1 via real-time PCR were performed to evaluate the megakaryocyte differentiation. Results: The results showed that PL insignificantly enhanced UCB CD34+ cell expansion (32.83± 8.47 fold in FBS and 41.67± 10.31 fold in PL containing media). Besides, flow cytometry results showed that expression of CD41 was increased markedly (37.81± 4.78 fold in FBS and 45.78 ± 7.37 in PL containing media, P-value <0.05) but the elevation of CD42b (10.53 ± 2.13 and 13.20 ± 2.06 in FBS and PL containing media, respectively) was not significant (P-value = 0.051). The results of real-time PCR demonstrated a notable increase in GATA binding protein 1 (1.58, P-value <0.01), GATA binding protein 2 (2.45, P-value <0.001), RUNX family transcription factor 1 (1.60, P-value <0.01), Fli-1 proto-oncogene (1.87, P-value <0.001) in PL supplemented media, however, the increase of Nuclear Factor-Erythroid 2 gene expression was not significant in PL supplemented media (P- value = 0.11). Conclusion: PL improved UCB CD34+ cells expansion and megakaryocyte differentiation compared to FBS. Downloaded from ijpho.ssu.ac.ir at 3:11 IRST on Wednesday September 29th 2021 [ DOI: 10.18502/ijpho.v11i3.6563 ] Keywords: Cord Blood Stem Cell Transplantation, Hematopoietic Stem Cells, Megakaryocyte Progenitor Cells, Platelet-Derived Growth Factor Introduction HSCs can be separated from various Hematopoietic stem cells (HSCs) are a sources such as BM or mobilized peripheral small population of nucleated cells that blood (MPB) progenitor cells and umbilical have the potential to differentiate into cord blood (UCB) for the treatment of mature cells of all hematopoietic lineages hematologic disorders (3, 4). Among and self-renewal capacity for maintenance different sources of HSCs, UCB is an of HSC pool in bone marrow (BM) (1, 2). attractive source for transplantation due to superior proliferative capacity, low risk for Yaghoubi et al transmission of pathogenic agents, low zoonotic contamination (especially prions, incidence of graft versus host disease bovine diarrhea virus, mycoplasma, (GVHD), relative availability, and ease of creutzfeldt Jacob virus, viruses, and isolation (5). HSCs number in a single cord parvovirus), high cost, xenogeneic immune blood (CB) unit is acceptable for reactions, antibodies production against hematopoietic reconstruction in children. non-native proteins, inflammation, However, UCB-HSCs have some production of non-homologous immune disadvantages, for instance, the HSCs response (which leads to the transplant number in a single CB unit is insufficient rejection), batch-to-batch variation, fetus for an adult patient so this can lead to a scarification during sample collection, and delayed or failed reconstruction of the ethical issues regarding the animal welfare hematopoietic system (5, 6). UCB-HSCs (15-19). Due to the drawbacks of serum- are immature, therefore, more cell divisions free culture medium as well as animal are needed before differentiation. serum, it is imperative to search for an Following UCB transplantation, it could alternative human resource. These delay platelet recoveries (6). Allogenic alternatives are autologous and allogeneic platelet transplantation after HSCs serum albumin, human serum, umbilical transplantation has some disadvantages cord blood serum, plasma derivative including bacteremia, alloimmunization, material, platelet derivatives, and acellular high-cost, and febrile reactions. Using Wharton’s jelly (15, 20). A high megakaryocyte progenitor along with the concentration of growth factors available in immature hematopoietic stem/progenitor platelet lysate (PL) makes it a proper cells (HSPCs) during the first few months replacement for animal serum in cell after transplantation can support short-term culture (21). PL granules, specially α- platelet production (7, 8). Cultivation of granules, release various cytokines and HSCs and generation of megakaryocyte- growth factors including chemokine ligand committed cells could lead to rapid cell 2(C¬XCL2), CXCL4 (PF4), CXCL10, reconstitution and shorten the period of CXCL12 (SDF-1), CXCL1, CXCL3, thrombocytopenia after HSCs CXCL5, granulocyte-macrophage colony- transplantation (6, 7). Differentiation of stimulating factor (GM-CSF), granulocyte- cells toward the megakaryocyte-platelet colony stimulating factor (G-CSF), linage requires the expression of specific connective tissue growth factor (CTGF), glycoproteins such as CD41 (glycoprotein hepatocyte growth factor (HGF), platelet- IIb), CD42b (glycoprotein Ib), and CD61 derived growth factor (PDGF), epidermal (glycoprotein IIIa) (9-12). These growth factor (EGF), insulin-like growth glycoproteins are involved in platelet factor-I (IGF-I), and basic fibroblast- aggregation/function and facilitate the derived growth factor (b-FGF). Compared identification and isolation of to FBS, the promotion of proliferation and megakaryocyte cells (13). Cell culture is differentiation of cells observed in PL may Downloaded from ijpho.ssu.ac.ir at 3:11 IRST on Wednesday September 29th 2021 [ DOI: 10.18502/ijpho.v11i3.6563 ] required for cell proliferation in vitro. Some be due to the abundance of growth factors mediums are serum-free which have some and cytokines with synergic effect (21-24). disadvantages including high cost and need In the current study, the effect of PL as a a protein/growth factor supplement, and substitute for PBS on the HSCs culture and some others, need supplementation with megakaryocyte differentiation has been animal or human serum (14, 15). In cell investigated. culture, fetal bovine serum (FBS) supplement has been considered as the gold Materials and Methods standard media, however, clinical use of PL procurement FBS has some limitations including In this experimental study, PL preparation transmission possibility of pathogens, was performed via freeze/thaw protocol Iran J Ped Hematol Oncol. 2021, Vol 11, No 3, 172-182 173 The Effect of Platelet Lysate on Expansion and Differentiation Megakaryocyte Progenitor Cells from Cord Blood CD34+ enriched Cells from platelet bags obtained from the Iranian Cell expansion assay Blood Transfusion Organization. Briefly, To evaluate the UCB CD34+ cells 10 bags of platelet (isolated from peripheral expansion, the culture was collected and the blood) were collected, and PL was prepared cells counted using the Trypan Blue (Gibco, by freeze/thaw protocol. The pooled USA) on day 8. To determine expansion platelet bags were frozen at -80°C/24 hour fold, counted viable cells on day 8 were and subsequently thawed three times at 37 divided by the cells seeded on the first day. °C to release PDGFs available in platelets. 2.5 Immunophenotypic marker analysis Then, bags were centrifuged at 4000 g/15 Megakaryocyte lineage markers were min at 4 °C, and to isolate leukocytes along evaluated by the flow cytometry with platelet fragments, the supernatant was (FACSCalibur, Becton Dickinson, US) on filtered by 0.2μm filter. For future use, PL day 8 in both culture conditions. Cells were was stored at -80°C (25). incubated with monoclonal antibodies including CD41-FITC, and CD42b-PE UCB CD34+ cell selection (both from Beckman Coulter, France) for After receiving informed consent,
Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors

    ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors

    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
  • Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3

    Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3

    RX Zhang, et al ORIGINAL ARTICLE Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3 1 Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China 2 Department of Otolaryngology , Jinan General Hospital of PLA, Shandong, China 3 Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai, China ■ Abstract Objective: To analyze the roles of chemokines and their receptors in the pathogenesis of allergic rhinitis by observing the complementary DNA (cDNA) expression of the chemokines and their receptors in the nasal mucosa of patients with and without allergic rhinitis, using gene chips. Methods: The total RNAs were isolated from the nasal mucosa of 20 allergic rhinitis patients and purifi ed to messenger RNAs, and then reversely transcribed to cDNAs and incorporated with samples of fl uorescence-labeled with Cy5-dUPT (rhinitis patient samples) or Cy3- dUTP (control samples of nonallergic nasal mucosa). Thirty-nine cDNAs of chemokines and their receptors were latticed into expression profi le chips, which were hybridized with probes and then scanned with the computer to study gene expression according to the different fl uorescence intensities. Results: The cDNAs of the following chemokines were upregulated: CCL1, CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL24, and CX3CL1 in most of the allergic rhinitis sample chips. CCR2, CCR3, CCR4, CCR5, CCR8 and CX3CR1 were the highly expressed receptor genes. Low expression of CXCL4 was found in these tissues. Conclusion: The T helper cell (TH) immune system is not well regulated in allergic rhinitis.
  • Chemochine E Immunità

    Chemochine E Immunità

    Chemochine e Immunità Mariagrazia Uguccioni AIBT 2016 – Pesaro 1987 – Discovery of the first “chemotactic cytokine” – IL8 Marco Baggiolini Theodor Kocher Institute University of Bern (CH) The Chemokine System - 2016 CCL23 CXCL8 CCL15 CXCL7 CCL14 CXCL6 CCL13 CXCL5 CXCL8 CXCL3 CCL8 CXCL6 CCL7 CXCL11 CXCL2 CXCL1 CCL5 CCL13 CXCL10 CCL3 CCL8 CXCR1 CXCL9 CCL7 CCL26 CXCR2 CCR1 CCL2 CCL13 CXCR3 CCL11 CXCL12 CCR2 CCL8 CCL7 CXCR4 CCL5 CCR3 CXCL13 CXCR5 CCL22 CCL17 CCR4 CXCL16 CXCR6 CCL3 CCR5 CCL4 CXCL17 CXCR8 CCL5 CCL8 CCR6 CX3CR1 CCL20 CX3CL1 XCR1 CCR7 XCL1 CCL19 CCR10 CCR8 XCL2 CCR9 CCL21 CCL27 CCL1 CCL28 CCL25 Cell Migration Selectin-mediated rolling 1 Chemoattractan signalling 2 Integrin-mediated cell adhesion 3 Step 1: attachement and rolling Migration along Step 2: activation chemotactic gradient Step 3: arrest and adhesion Chemokine source Functional Modules in Cell Migration T naive IL-2 CCR7 mature DC Priming B naive IL-6 CXCR5 FDC, TFH Antibody immature DC GM-CSF CCR1, CCR5 T naive Antigen uptake TH1 IFN- CCR5 M Bacteria TH2 IL-4, IL-5 CCR3 Eos/Bas Parasites TH17 IL-17, IL-22 CCR6 Neut Fungi CTL IFN-, Perf CXCR3 M Virus From Blood to Tissue CCR1 Tissue Blood CCR2 CCR2 CCR5 CXCR3 From Tissue to Lymph Nodes CCL21 Lymph nodes are privileged sites normal for dendritic cell-naïve T cell encounters CCL21 CCR7 CCL21 inflamed CCL19 from S. Lira, Nat Immunol 2005, 6:866. Functional Modules in Cell Migration T naive IL-2 CCR7 mature DC Priming B naive IL-6 CXCR5 FDC, TFH Antibody immature DC GM-CSF CCR1, CCR5 T naive Antigen uptake TH1 IFN- CCR5
  • The Chemokine System in Innate Immunity

    The Chemokine System in Innate Immunity

    Downloaded from http://cshperspectives.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press The Chemokine System in Innate Immunity Caroline L. Sokol and Andrew D. Luster Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 Correspondence: [email protected] Chemokines are chemotactic cytokines that control the migration and positioning of immune cells in tissues and are critical for the function of the innate immune system. Chemokines control the release of innate immune cells from the bone marrow during homeostasis as well as in response to infection and inflammation. Theyalso recruit innate immune effectors out of the circulation and into the tissue where, in collaboration with other chemoattractants, they guide these cells to the very sites of tissue injury. Chemokine function is also critical for the positioning of innate immune sentinels in peripheral tissue and then, following innate immune activation, guiding these activated cells to the draining lymph node to initiate and imprint an adaptive immune response. In this review, we will highlight recent advances in understanding how chemokine function regulates the movement and positioning of innate immune cells at homeostasis and in response to acute inflammation, and then we will review how chemokine-mediated innate immune cell trafficking plays an essential role in linking the innate and adaptive immune responses. hemokines are chemotactic cytokines that with emphasis placed on its role in the innate Ccontrol cell migration and cell positioning immune system. throughout development, homeostasis, and in- flammation. The immune system, which is de- pendent on the coordinated migration of cells, CHEMOKINES AND CHEMOKINE RECEPTORS is particularly dependent on chemokines for its function.
  • US 2017/0020926 A1 Mata-Fink Et Al

    US 2017/0020926 A1 Mata-Fink Et Al

    US 20170020926A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020926 A1 Mata-Fink et al. (43) Pub. Date: Jan. 26, 2017 (54) METHODS AND COMPOSITIONS FOR 62/006,825, filed on Jun. 2, 2014, provisional appli MMUNOMODULATION cation No. 62/006,829, filed on Jun. 2, 2014, provi sional application No. 62/006,832, filed on Jun. 2, (71) Applicant: RUBIUS THERAPEUTICS, INC., 2014, provisional application No. 61/991.319, filed Cambridge, MA (US) on May 9, 2014, provisional application No. 61/973, 764, filed on Apr. 1, 2014, provisional application No. (72) Inventors: Jordi Mata-Fink, Somerville, MA 61/973,763, filed on Apr. 1, 2014. (US); John Round, Cambridge, MA (US); Noubar B. Afeyan, Lexington, (30) Foreign Application Priority Data MA (US); Avak Kahvejian, Arlington, MA (US) Nov. 12, 2014 (US) ................. PCT/US2O14/0653O4 (21) Appl. No.: 15/301,046 Publication Classification (22) PCT Fed: Mar. 13, 2015 (51) Int. Cl. A6II 35/28 (2006.01) (86) PCT No.: PCT/US2O15/02O614 CI2N 5/078 (2006.01) (52) U.S. Cl. S 371 (c)(1), CPC ............. A61K 35/28 (2013.01); C12N5/0641 (2) Date: Sep. 30, 2016 (2013.01): CI2N 5/0644 (2013.01); A61 K Related U.S. Application Data 2035/122 (2013.01) (60) Provisional application No. 62/059,100, filed on Oct. (57) ABSTRACT 2, 2014, provisional application No. 62/025,367, filed on Jul. 16, 2014, provisional application No. 62/006, Provided are cells containing exogenous antigen and uses 828, filed on Jun. 2, 2014, provisional application No.
  • Role of Chemokines in Hepatocellular Carcinoma (Review)

    Role of Chemokines in Hepatocellular Carcinoma (Review)

    ONCOLOGY REPORTS 45: 809-823, 2021 Role of chemokines in hepatocellular carcinoma (Review) DONGDONG XUE1*, YA ZHENG2*, JUNYE WEN1, JINGZHAO HAN1, HONGFANG TUO1, YIFAN LIU1 and YANHUI PENG1 1Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang, Hebei 050051; 2Medical Center Laboratory, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, P.R. China Received September 5, 2020; Accepted December 4, 2020 DOI: 10.3892/or.2020.7906 Abstract. Hepatocellular carcinoma (HCC) is a prevalent 1. Introduction malignant tumor worldwide, with an unsatisfactory prognosis, although treatments are improving. One of the main challenges Hepatocellular carcinoma (HCC) is the sixth most common for the treatment of HCC is the prevention or management type of cancer worldwide and the third leading cause of of recurrence and metastasis of HCC. It has been found that cancer-associated death (1). Most patients cannot undergo chemokines and their receptors serve a pivotal role in HCC radical surgery due to the presence of intrahepatic or distant progression. In the present review, the literature on the multi- organ metastases, and at present, the primary treatment methods factorial roles of exosomes in HCC from PubMed, Cochrane for HCC include surgery, local ablation therapy and radiation library and Embase were obtained, with a specific focus on intervention (2). These methods allow for effective treatment the functions and mechanisms of chemokines in HCC. To and management of patients with HCC during the early stages, date, >50 chemokines have been found, which can be divided with 5-year survival rates as high as 70% (3). Despite the into four families: CXC, CX3C, CC and XC, according to the continuous development of traditional treatment methods, the different positions of the conserved N-terminal cysteine resi- issue of recurrence and metastasis of HCC, causing adverse dues.
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells with an Increased Cytotoxic Potential

    CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells with an Increased Cytotoxic Potential

    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
  • Chemokines and Their Receptors in Rheumatoid Arthritis

    Chemokines and Their Receptors in Rheumatoid Arthritis

    ARTHRITIS & RHEUMATISM Vol. 52, No. 3, March 2005, pp 710–721 DOI 10.1002/art.20932 © 2005, American College of Rheumatology REVIEW Chemokines and Their Receptors in Rheumatoid Arthritis Future Targets? Alisa E. Koch Introduction tem was introduced in 2000, in which chemokines are considered as chemokine ligands, and each chemokine Rheumatoid arthritis (RA) is a chronic inflam- has been assigned a designation of CXCL, CCL, XCL, matory disease leading to joint destruction (1). In RA, or CX3CL1 (Figure 1) (10–12). In this report, both the migration of leukocytes into the synovial tissue (ST) former and new nomenclature are noted. occurs. These leukocytes and other cells in the ST, particularly RA ST fibroblasts, produce mediators of CXC chemokines have 2 conserved cysteines inflammation, including chemokines (1). Chemokines, separated by 1 unconserved amino acid (9,13) (Figure currently numbering more than 50, are chemotactic 1). CXC chemokines classically were thought to be cytokines that are important in recruitment of leuko- involved in the chemotaxis of neutrophils. Many chemo- cytes and angiogenesis. They exert chemotactic activity kines may have arisen from reduplication of ancestral toward a variety of cell types (2–7). Some chemokines, genes (13). Hence, CXC chemokines that act on neutro- particularly CXC chemokines containing the ELR motif, phils are clustered on chromosome 4q12–13 (13). How- are angiogenic. The last few years have seen a rapid ever, some genes of more newly discovered CXC che- development of studies aimed at targeting proinflamma- mokines that recruit lymphocytes tend to be located tory chemokines or their receptors in RA and animal away from the major clusters (13).
  • Human Platelet Lysate As a Functional Substitute for Fetal Bovine Serum in the Culture of Human Adipose Derived Stromal/Stem Cells

    Human Platelet Lysate As a Functional Substitute for Fetal Bovine Serum in the Culture of Human Adipose Derived Stromal/Stem Cells

    Brief Report Human Platelet Lysate as a Functional Substitute for Fetal Bovine Serum in the Culture of Human Adipose Derived Stromal/Stem Cells Mathew Cowper 1,†, Trivia Frazier 1,2,3, Xiying Wu 2,3, Lowry Curley 2,4, Michelle H. Ma 3, Omair A. Mohuiddin 1, Marilyn Dietrich 5, Michelle McCarthy 1, Joanna Bukowska 1,6 and Jeffrey M. Gimble 1,2,3,* 1 School of Medicine, Tulane University, New Orleans, LA 70112, USA 2 LaCell LLC, New Orleans, LA 70148, USA 3 Obatala Sciences Inc., New Orleans, LA 70148, USA 4 Axosim Sciences Inc., New Orleans, LA 70803, USA 5 Louisiana State University School of Veterinary Medicine, Baton Rouge, LA 70803, USA 6 Institute for Animal Reproduction and Food Research, Polish Academy of Science, 10-748 Olsztyn, Poland * Correspondence: [email protected]; Tel.: 1-(504)-300-0266 † Current Affiliations: Department of Urology, Bowman Gray School of Medicine, Wake Forest University, Winston Salem, NC 27101, USA. Received: 15 May 2019; Accepted: 9 July 2019; Published: 15 July 2019 Abstract: Introduction: Adipose derived stromal/stem cells (ASCs) hold potential as cell therapeutics for a wide range of disease states; however, many expansion protocols rely on the use of fetal bovine serum (FBS) as a cell culture nutrient supplement. The current study explores the substitution of lysates from expired human platelets (HPLs) as an FBS substitute. Methods: Expired human platelets from an authorized blood center were lysed by freeze/thawing and used to examine human ASCs with respect to proliferation using hematocytometer cell counts, colony forming unit- fibroblast (CFU-F) frequency, surface immunophenotype by flow cytometry, and tri-lineage (adipocyte, chondrocyte, osteoblast) differentiation potential by histochemical staining.
  • Chemokines and Chemokine Receptors in Neurological Disease: Raise, Retain, Or Reduce?

    Chemokines and Chemokine Receptors in Neurological Disease: Raise, Retain, Or Reduce?

    Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Chemokines and Chemokine Receptors in Neurological Disease: Raise, Retain, or Reduce? Carine Savarin-Vuaillat* and Richard M. Ransohoff*† *Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, and †Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195. Summary: Chemokines and chemokine receptors comprise a specific expression in A␤ plaques, may be a marker for Alzheimer large number of molecules implicated in a wide range of physio- pathology. Downregulation of CCL2 in cerebrospinal fluid may be logical and pathological functions. Numerous studies have dem- a candidate to characterize multiple sclerosis (MS), but needs onstrated the roles of chemokines and chemokine receptors: 1) additional investigation. Moreover, chemokines and chemokine during development, by regulating hematopoiesis, cardiogenesis, receptors represent interesting therapeutic targets. Using chemo- and vascular and cerebellar development; 2) during tumor biology, kine receptor antagonists, several studies provided exciting find- by controlling cell proliferation, angiogenesis, and metastasis; and ings for potential neurological disease treatment. Chemokine re- 3), especially during leukocyte migration, by acting on firm ad- ceptor antagonists reduce disease severity in animal models of hesion, locomotion, diapedesis, and chemotaxis. This review fo- MS. In glioblastoma, a CXCR4 antagonist (AMD3100) showed cuses on chemokine and chemokine receptor involvement in di- an inhibition of tumor growth. Inhibition of chemokine recep- verse neurological diseases and their therapeutic potentials. tor signaling is not the only therapeutic strategy: for exam- Because of its induction or upregulation during CNS pathologies, ple, CXCR4–CXCL12 has anti-inflammatory properties and members of the chemokine system can be used as biological CX3CL1–CX3CR1 controls neurotoxicity.
  • Human XCL2 Protein (His Tag)

    Human XCL2 Protein (His Tag)

    Human XCL2 Protein (His Tag) Catalog Number: 13502-H08B General Information SDS-PAGE: Gene Name Synonym: SCM-1b; SCM1B; SCYC2 Protein Construction: A DNA sequence encoding the human XCL2 (Q9UBD3) (Met 1-Gly 114) was fused with a polyhistidine tag at the C-terminus. Source: Human Expression Host: Baculovirus-Insect Cells QC Testing Purity: > 90 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method XCL2 is a small cytokine belonging to the XC chemokine family. Stability: Chemokines are a group of cytokines. Members of this group of so-called C-Chemokines belong to the SCY family of cytokines and are designated Samples are stable for up to twelve months from date of receipt at -70 ℃ XCL (L for ligand) followed by a number. XCL2 is the new designation of SCM-1-beta. XCL2 is highly related to another chemokine called XCL1. Predicted N terminal: Val 22 XCL2 gene is located on chromosome 1 in humans. XCL2 is predominantly Molecular Mass: expressed in activated T cells, but can also be found at low levels in unstimulated cells. XCL2 induces chemotaxis of cells expressing the The secreted recombinant human XCL2 comprises 103 amino acids and chemokine receptor XCR1. XCL2 gene has been proposed to participate in has a predicted molecular mass of 11.7 kDa. The apparent molecular pathways (Chemokine signaling pathway, Cytokine-cytokine receptor mass of rh XCL2 is approximately 18-20 kDa in SDS-PAGE under interaction) and processes (blood circulation, signal transduction, reducing conditions. chemotaxis, immune response).
  • Review Article the Roles of Platelets in Inflammation, Immunity, Wound Healing and Malignancy

    Review Article the Roles of Platelets in Inflammation, Immunity, Wound Healing and Malignancy

    Int J Clin Exp Med 2016;9(3):5347-5358 www.ijcem.com /ISSN:1940-5901/IJCEM0021296 Review Article The roles of platelets in inflammation, immunity, wound healing and malignancy Ymer H Mekaj1,2 1Institute of Pathophysiology, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo; 2Department of Hemostasis and Thrombosis, National Blood Transfusion Center of Kosovo, Prishtina, Kosovo Received December 6, 2015; Accepted March 10, 2016; Epub March 15, 2016; Published March 30, 2016 Abstract: The roles of platelets as essential effector cells in hemostasis have been known for over a century. Platelets also have many other functions, which are facilitated by their complex morphological structures and their ability to synthesize and store a variety of biochemical substances. These substances are released via the platelet release re- action in response to tissue/cell damage. The aim of the current study was to review the reported functions of plate- lets in inflammation, immunity, wound healing and malignancy. For this purpose, we used relevant data from the latest numerous scientific studies, including review articles, and original research articles. Platelets physiologically respond to inflammation by recruiting inflammatory cells to repair and resolve injuries. This response is facilitated by the ability of platelets to promote vascular permeability under inflammatory conditions. Platelets have critical roles in innate and adaptive immune responses and extensively interact with endothelial cells, various pathogens, and almost all known immune cell types, including neutrophils, monocytes, macrophages and lymphocytes. Additionally, platelets affect wound healing by integrating complex cascades between their mediators, which include multiple cytokines, transforming growth factors, platelet growth factors, and vascular endothelial growth factors, among oth- ers.